Do Ozempic and Wegovy slow aging? What the new research shows
Semaglutide, the active ingredient in Ozempic and Wegovy, has transformed weight management over the past few years. Now researchers are asking whether the same drug might also slow how quickly the body ages biologically, and a new study offers the first concrete clinical evidence pointing in that direction.
The research was conducted in adults living with HIV. That group was chosen specifically because HIV infection is associated with accelerated biological aging, driven by chronic inflammation, meaning people living with HIV can carry aging markers that look "older" than their actual chronological age would suggest.
The term "biological aging markers" refers to laboratory measures of how old your cells and DNA actually appear, as distinct from the age shown on your birth certificate. Among the most prominent of these measures are epigenetic clocks, tests that track how chemical markers on DNA change as a person ages.
Researchers found that HIV-positive adults taking semaglutide showed slower progression of these biological aging markers compared with those not taking the drug. It is being described as the first clinical evidence, in real human patients rather than lab animals, that the drug may influence human aging.
Scientists say the finding is exciting but still early stage. The study cannot yet fully distinguish whether the slowdown is driven by weight loss itself, the drug's primary intended effect, or by semaglutide's direct effects on metabolism and inflammation independent of weight change.
That distinction matters. If the effect is purely a byproduct of weight loss, that is already a known and expected outcome. But if semaglutide itself, through some independent mechanism, is slowing cellular aging, that would be a far broader finding with implications for how the drug might eventually be used.
Researchers also note the study was conducted in a specific population living with HIV, so the results cannot be directly generalised to the wider population. Chronic inflammation linked to HIV can affect aging markers in ways that may not translate identically to people without the condition.
Experts are clear that the findings should not be read as "Ozempic makes you younger." The drug is currently approved for treating type 2 diabetes and obesity; it is not prescribed to slow aging, and no regulator has approved it for that purpose.
Still, the finding contributes to a growing body of research suggesting that GLP-1 agonist drugs may affect more than just weight and blood sugar, potentially influencing the body's broader inflammatory and metabolic health profile. Scientists say larger, more diverse patient studies will be needed to confirm whether the effect holds up.
For now, the takeaway is that the first concrete evidence of semaglutide's effect on human biological aging has emerged, but it is far too early to treat the drug as an anti-aging therapy, and scientists are waiting on the results of larger clinical trials before drawing firmer conclusions.
Read next
Second death reported in New York City legionnaires' disease outbreak
A second person has died in a legionnaires' disease outbreak that has sickened dozens of people in New York City, health officials say, even as they report evidence the source of the bacteria has likely been eliminated.
A common antidepressant may ease long COVID's crushing fatigue, trial finds
A randomized clinical trial of nearly 400 adults found that fluvoxamine, a low-cost, decades-old antidepressant, significantly reduced fatigue and improved quality of life in people with long COVID, making it one of the first medications to show a meaningful benefit for the debilitating symptom.
Mineral sunscreen without the chalky white cast: what UCLA's new formula changes
Mineral sunscreens are prized for being gentler on skin than chemical alternatives, but they have long left users with a visible white cast. Scientists at UCLA say they have redesigned the zinc oxide particles at the heart of the problem, aiming to make mineral sunscreen usable across all skin tones.
Menopause hormone therapy: what it actually treats, and what it doesn't
Menopause hormone therapy has swung from being widely feared to widely recommended, but doctors say expectations have overtaken the evidence. Here is what the treatment reliably helps with, what it doesn't, and how the science has shifted over two decades.
FDA still points to Taylor Farms lettuce in cyclospora outbreak despite a faulty test
US regulators say they remain focused on lettuce supplied by Taylor Farms as the likely source of a multistate cyclospora outbreak, even after one laboratory test used to support that theory turned out to be faulty. Restaurant visits tied to the outbreak have started to decline.